DEFLAZACORT

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C25H31NO6
Molecular Weight	441.5167
Optical Activity	UNSPECIFIED
Defined Stereocenters	8 / 8
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of DEFLAZACORT

Structure Search

SMILES

[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(N=C(C)O2)C(=O)COC(C)=O

InChI

InChIKey=FBHSPRKOSMHSIF-GRMWVWQJSA-N

InChI=1S/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h7-9,17-19,21-22,29H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22+,23-,24-,25+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C25H31NO6
Molecular Weight	441.5167
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	7 / 8
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:24:36 UTC 2023` Edited by `admin` on `Fri Dec 15 15:24:36 UTC 2023`
Record UNII	KR5YZ6AE4B
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DEFLAZACORT

Official Name

English

EMFLAZA

Brand Name

English

DEFLAZACORT [USP-RS]

Common Name

English

11.BETA.,21-DIHYDROXY-2'-METHYL-5'.BETA.H-PREGNA-1,4-DIENO(17,16-D)OXAZOLE-3,20-DIONE 21-ACETATE

Common Name

English

DEFLAZACORT [MI]

Common Name

English

Deflazacort [WHO-DD]

Common Name

English

MDL-458

Code

English

DEFLAZACORT [USAN]

Common Name

English

DEFLAZACORT [ORANGE BOOK]

Common Name

English

MDL458

Code

English

deflazacort [INN]

Common Name

English

5'H-PREGNA-1,4-DIENO(17,16-D)OXAZOLE-3,20-DIONE, 21-(ACETYLOXY)-11-HYDROXY-2'-METHYL-, (11.BETA.,16.BETA.)-

Common Name

English

DEFLAZACORT [MART.]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C521

Created by admin on Fri Dec 15 15:24:37 UTC 2023 , Edited by admin on Fri Dec 15 15:24:37 UTC 2023

FDA ORPHAN DRUG

491715

Created by admin on Fri Dec 15 15:24:37 UTC 2023 , Edited by admin on Fri Dec 15 15:24:37 UTC 2023

FDA ORPHAN DRUG

315110

Created by admin on Fri Dec 15 15:24:37 UTC 2023 , Edited by admin on Fri Dec 15 15:24:37 UTC 2023

WHO-VATC

QH02AB13

Created by admin on Fri Dec 15 15:24:37 UTC 2023 , Edited by admin on Fri Dec 15 15:24:37 UTC 2023

FDA ORPHAN DRUG

403413

Created by admin on Fri Dec 15 15:24:37 UTC 2023 , Edited by admin on Fri Dec 15 15:24:37 UTC 2023

WHO-ATC

H02AB13

Created by admin on Fri Dec 15 15:24:37 UTC 2023 , Edited by admin on Fri Dec 15 15:24:37 UTC 2023

NDF-RT

N0000175576

Created by admin on Fri Dec 15 15:24:37 UTC 2023 , Edited by admin on Fri Dec 15 15:24:37 UTC 2023

Code System Code Type Description

LACTMED

Deflazacort

Created by admin on Fri Dec 15 15:24:37 UTC 2023 , Edited by admin on Fri Dec 15 15:24:37 UTC 2023

PRIMARY

MERCK INDEX

m4135

Created by admin on Fri Dec 15 15:24:37 UTC 2023 , Edited by admin on Fri Dec 15 15:24:37 UTC 2023

PRIMARY

Merck Index

EPA CompTox

DTXSID9020378

Created by admin on Fri Dec 15 15:24:37 UTC 2023 , Edited by admin on Fri Dec 15 15:24:37 UTC 2023

PRIMARY

RS_ITEM_NUM

1166116

Created by admin on Fri Dec 15 15:24:37 UTC 2023 , Edited by admin on Fri Dec 15 15:24:37 UTC 2023

PRIMARY

ECHA (EC/EINECS)

238-483-7

Created by admin on Fri Dec 15 15:24:37 UTC 2023 , Edited by admin on Fri Dec 15 15:24:37 UTC 2023

PRIMARY

DAILYMED

KR5YZ6AE4B

Created by admin on Fri Dec 15 15:24:37 UTC 2023 , Edited by admin on Fri Dec 15 15:24:37 UTC 2023

PRIMARY

DRUG BANK

DB11921

Created by admin on Fri Dec 15 15:24:37 UTC 2023 , Edited by admin on Fri Dec 15 15:24:37 UTC 2023

PRIMARY

WIKIPEDIA

Deflazacort

Created by admin on Fri Dec 15 15:24:37 UTC 2023 , Edited by admin on Fri Dec 15 15:24:37 UTC 2023

PRIMARY

FDA UNII

KR5YZ6AE4B

Created by admin on Fri Dec 15 15:24:37 UTC 2023 , Edited by admin on Fri Dec 15 15:24:37 UTC 2023

PRIMARY

ChEMBL

CHEMBL1201891

Created by admin on Fri Dec 15 15:24:37 UTC 2023 , Edited by admin on Fri Dec 15 15:24:37 UTC 2023

PRIMARY

INN

4323

Created by admin on Fri Dec 15 15:24:37 UTC 2023 , Edited by admin on Fri Dec 15 15:24:37 UTC 2023

PRIMARY

CAS

14484-47-0

Created by admin on Fri Dec 15 15:24:37 UTC 2023 , Edited by admin on Fri Dec 15 15:24:37 UTC 2023

PRIMARY

RXCUI

22396

Created by admin on Fri Dec 15 15:24:37 UTC 2023 , Edited by admin on Fri Dec 15 15:24:37 UTC 2023

PRIMARY

RxNorm

NCI_THESAURUS

C87230

Created by admin on Fri Dec 15 15:24:37 UTC 2023 , Edited by admin on Fri Dec 15 15:24:37 UTC 2023

PRIMARY

DRUG CENTRAL

793

Created by admin on Fri Dec 15 15:24:37 UTC 2023 , Edited by admin on Fri Dec 15 15:24:37 UTC 2023

PRIMARY

PUBCHEM

189821

Created by admin on Fri Dec 15 15:24:37 UTC 2023 , Edited by admin on Fri Dec 15 15:24:37 UTC 2023

PRIMARY

SMS_ID

100000092093

Created by admin on Fri Dec 15 15:24:37 UTC 2023 , Edited by admin on Fri Dec 15 15:24:37 UTC 2023

PRIMARY

USAN

X-95

Created by admin on Fri Dec 15 15:24:37 UTC 2023 , Edited by admin on Fri Dec 15 15:24:37 UTC 2023

PRIMARY

EVMPD

SUB06943MIG

Created by admin on Fri Dec 15 15:24:37 UTC 2023 , Edited by admin on Fri Dec 15 15:24:37 UTC 2023

PRIMARY

MESH

C021988

Created by admin on Fri Dec 15 15:24:37 UTC 2023 , Edited by admin on Fri Dec 15 15:24:37 UTC 2023

PRIMARY

Related Record Type Details


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Interaction Type:

BINDING

Amount:


					22ES734693

MULTIDRUG RESISTANCE PROTEIN 1

TRANSPORTER -> SUBSTRATE


					FZW85LW99M

GLUCOCORTICOID RECEPTOR

TARGET -> INHIBITOR


					PUO0521HZV

CYTOCHROME P450 3A4

METABOLIC ENZYME -> INHIBITOR

Comments:

- Co-administration of deflazacort with clarithromycin, a strong CYP3A4 inhibitor, increased total exposure to 21-desDFZ by about 3-fold. - Co-administration of deflazacort with rifampin, a strong CYP3A4 inducer, significantly decreased the exposure of 21-desDFZ.

Related Record Type Details


					T1LWN33J2P

21-DESACETYLDEFLAZACORT

METABOLITE ACTIVE -> PRODRUG


					L93L6AWV7W

6BETA-HYDROXY-21-DESACETYL DEFLAZACORT

METABOLITE INACTIVE -> PARENT

Related Record Type Details


					T1LWN33J2P

21-DESACETYLDEFLAZACORT

ACTIVE MOIETY

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Tmax	PHARMACOKINETIC				ORAL ADMINISTRATION

Biological Half-life	PHARMACOKINETIC